Daybu
What Daybu is used for
Daybu is indicated for the treatment of neurobehavioural symptoms of Rett syndrome in adults and paediatric patients aged 5 years and older.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Daybu
- Active substance
- trofinetide
- Disease area
- Rett Syndrome
- Medicine group
- Other nervous system drugs
- ATC code
- N07XX24
- Marketing authorisation holder
- Acadia Pharmaceuticals B.V.
- Authorised in the EU since
- 2026
Official information
In the USA
Same active substance: Daybue Stix, Daybue
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Daybu used for?
Daybu is indicated for the treatment of neurobehavioural symptoms of Rett syndrome in adults and paediatric patients aged 5 years and older.
What is the active substance in Daybu?
Daybu contains trofinetide.
Who makes Daybu?
The EU marketing authorisation holder is Acadia Pharmaceuticals B.V..
Is Daybu an orphan medicine?
Yes. Daybu is designated an orphan medicine in the EU, for a rare disease (Rett Syndrome).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU